GCC SMA incidence runs 40-65% above the global rate, and country-level newborn-screening coverage, from 90% in Saudi Arabia to under 50% elsewhere, is the near-term lever on the gene-therapy-eligible pool.
SMA incidence in the GCC runs 1:6,000-8,000 live births versus roughly 1:10,000 globally, elevated by consanguinity increasing the probability of homozygous SMN1 deletion (Al-Jasmi F et al., Orphanet J Rare Dis 2016). Saudi Arabia alone sees an estimated 200-250 new SMA births annually, with the UAE contributing 30-35 and Qatar 20-25, a combined GCC total of roughly 300-350 new cases a year. Newborn-screening coverage is converting these from symptomatic clinical diagnoses to pre-symptomatic identifications at sharply different rates by country: an estimated 90% in Saudi Arabia as of 2023, 85% in the UAE, 75% in Qatar, and under 50% across the remaining GCC states, the near-term addressable-growth lever for gene-therapy-eligible volume.
Alongside the newborn-screening-identified pre-symptomatic pipeline sits a distinct legacy population: an estimated 800-1,200 GCC SMA Type 2/3 patients diagnosed before newborn screening existed, now teenagers and adults with established motor disability and ineligible for gene therapy on age and weight criteria. On the treatment side, this model anchors sizing against the observed 60-80 annual GCC Zolgensma cases under NPHC and MOH outcomes-based rebate arrangements, roughly $1.5-1.8M per patient against a $2.125M US list price, a bottom-up validation check against the top-down incidence-and-coverage estimate.
GCC spinal muscular atrophy funnel — from incidence to the Zolgensma on-therapy anchor
| Funnel Stage | Population | Source |
|---|---|---|
| GCC SMA incidence (combined new cases/yr) | 1:6,000-8,000 (~300-350/yr) | Al-Jasmi F et al., Orphanet J Rare Dis 2016 |
| Newborn-screening coverage by country | Saudi Arabia ~90%; UAE ~85%; Qatar ~75%; others under 50% | Saudi NBS Programme 2022-2023 |
| Legacy pre-NBS Type 2/3 adult pool (gene-therapy-ineligible) | 800-1,200 | GCC paediatric neurology network SMA registry 2022 |
| On-therapy anchor: annual GCC Zolgensma cases | 60-80/yr | NPHC/MOH outcomes-based rebate arrangements; Novartis GCC access documentation |
Sources: Al-Jasmi F et al., Orphanet J Rare Dis 2016; Saudi NBS Programme 2022-2023; GCC paediatric neurology network SMA registry 2022; NPHC SMA programme documentation 2022-2023; Novartis GCC access communications.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NBS coverage by country (Saudi Arabia ~90%, UAE ~85%, Qatar ~75%, others under 50%)
- the combined ~300-350/yr new case estimate
- gene-therapy-eligible birth-cohort sizing by country
Delivers
- 800-1,200-patient legacy cohort sizing
- gene-therapy age/weight ineligibility
- chronic-therapy (nusinersen/risdiplam) dependency
Delivers
- NPHC/MOH outcomes-based rebate structure
- GCC list price ($1.5-1.8M vs $2.125M US)
- bottom-up-versus-top-down reconciliation methodology
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why country-level newborn-screening coverage, not the combined GCC incidence figure alone, sets the near-term addressable pool
- Pressure-tested against the observed 60-80/yr Zolgensma volume before the funnel is built out
- 1:6,000-8,000 GCC incidence vs 1:10,000 global
- ~300-350/yr combined new cases across Saudi Arabia, the UAE, and Qatar
- Saudi Arabia ~90% / UAE ~85% / Qatar ~75% / others under 50%
- Specialist centre network: KAMC, KFSH&RC, Sidra Medicine, SKMC
- 800-1,200-patient legacy cohort diagnosed before newborn screening existed
- Gene-therapy age/weight ineligibility for this population
- Three-modality NPHC/MOH coverage across Type 1-3
- Outcomes-based milestone rebate structure for Zolgensma
- Which assumptions move the eligible pool most
- Scenario ranges across country-level NBS coverage assumptions
- Patient volume by horizon under conservative, base, and aggressive scenarios
- Revenue translation inputs
- The open questions your forecasting team must close before the model is finalised
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel: population and disease burden (E1), diagnosis and specialist capture (E2), subtype and severity eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. For GCC SMA, country-level newborn-screening coverage functions as the E2 capture mechanism, and the model separates the newborn-screening-identified pipeline from the pre-newborn-screening-era legacy Type 2/3 adult population, which follows a different, chronic-therapy-only access path.
GCC SMA sources: Al-Jasmi F et al., Orphanet J Rare Dis 2016, for the consanguinity-elevated incidence estimate; the Saudi National Newborn Screening Programme for country-level coverage; the GCC paediatric neurology network SMA registry for the legacy Type 2/3 cohort; and NPHC/MOH outcomes-based rebate documentation for the observed 60-80/yr Zolgensma on-therapy anchor.
- GCC SMA incidence and consanguinity-effect figures verified against Al-Jasmi F et al., Orphanet J Rare Dis 2016
- Newborn-screening coverage rates by country verified against Saudi NBS Programme 2022-2023 data
- Legacy Type 2/3 cohort sizing verified against the GCC paediatric neurology network SMA registry 2022
- 60-80/yr on-therapy Zolgensma volume and outcomes-based rebate structure verified against NPHC SMA programme documentation and Novartis GCC access communications
Frequently asked questions
Commission this model
AXLRx delivers rare disease patient flow models built for forecasting and launch teams sizing the GCC spinal muscular atrophy opportunity. Custom model in 72 hours.
Specify your indication, GCC country focus, and cohort definition.
AXLRx analyst confirms funnel scope and comparator set before building.
Research-verified patient flow model in 72 hours with optional analyst readout.